NCT06749860 2024-12-27Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionShanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 Recruiting58 enrolled